[1] American Cancer Society. Global Cancer Facts and Figures (2015). https://www.cancer.org/content/dam/cancerorg/research/cancer-factsand-statistics/global-cancerfacts-and-figures/globalcancer-facts-and-figures-3rdedition.pdf. Accessed 01-11-2018.
[2] American Cancer Society. Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/about/keystatistics.html. Accessed 01-08-2018.
[3] European Commission. Epidemiology of prostate cancer in Europe (03-17-2017). https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancereurope. Accessed 01-19-2018.
[4] Kirby M, Hirst C, Crawford ED. Characterising the castration resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92.
[4] Luo J, Beer T, Graff J. Treatment of nonmetastatic castration-resistant prostate cancer. Oncology 2016;30(4):336-44.
[6] Smith MR, Kabbinavar F, Saad F, Hussain A et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918?2925.
[7] [1] Hussain M, Fizazi K, Saad F, et al. PROSPER: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). ASCO
GU Meeting Library. https://meetinglibrary.asco.org/record/157683/abstract. Accessed 02-07-2018.
Home American Cancer Society. Global Cancer Facts and Figures
